US Archives - Page 52 of 80 - European Medical Journal

CAR T-Cell Therapy in Solid Tumors: Latest Developments

CAR T-cell therapy, a major advancement in treating hematologic cancers, has struggled to show consistent success in solid tumors.

Interview: John H Stone

Growing up I played football, but it quickly became clear that I probably would not become a professional player, so I began to consider…

Emerging Artemisinin Resistance in Severe Malaria

A new study highlights partial resistance to artemisinin in Ugandan children with severe malaria, raising concerns about the efficacy of frontline treatments in sub-Saharan Africa.

Novel Steroid-Sparing SLE Solution: ACR24

Evidence supporting a novel therapeutic target for systemic lupus erythematosus (SLE), the E3 ubiquitin ligase “E3-X”, was presented at ACR Convergence 2024 in Washington, D.C.

PI3K Pathway Identified as Key in SSc Skin Fibrosis: ACR2024

Researchers unveiled a groundbreaking study shedding light on the complex molecular interplay driving fibrosis in diffuse systemic sclerosis (dcSSc) at ACR 2024 in Washington, D.C., USA.

Cellular Impacts In Antisynthetase Syndrome: ACR24

New research into how antisynthetase autoantibodies disrupt critical enzymatic functions in muscle cells was presented as part of a plenary abstract session at ACR Convergence 2024 in Washington, D.C.

RISE-Registry Enrollment Elevates Care Quality: ACR24

Participation in the Rheumatology Informatics System for Effectiveness (RISE), an electronic heath record (EHR)-enabled registry designed by the American College of Rheumatology (ACR), significantly improves clinical care metrics, according to a study presented at ACR Convergence 2024.

Breakthrough in Hodgkin’s Treatment: Nivolumab+AVD

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

Air Quality and Eczema: New Health Findings

A recent study has found a significant association between fine particulate air pollution (PM2.5) and eczema, highlighting a potential environmental driver of the skin condition among American adults.

Efficacy and Safety of Upadacitinib in SELECT-GCA Phase III Trial Results: ACR24

A Phase III clinical trial presented at ACR Convergence 2024 revealed that upadacitinib (UPA), combined with a 26-week glucocorticoid (GC) improved disease control and reduced steroid exposure compared to a placebo (PBO) regimen in patients with giant cell arteritis (GCA).